Boehringer Ingelheim Venture Fund
Profile, fund size and portfolio
Boehringer Ingelheim Venture Fund is the corporate venture arm of Boehringer Ingelheim (pharmaceuticals). It was founded in 2010 and is based in Ingelheim am Rhein, Germany. It invests from Seed to Series A in cancer, regenerative medicine, auto-immunity indications.
Every figure links to its source
Snapshot
Data behind this graphic
| Item | Value |
|---|---|
| Stage range | Seed to Series A |
| Sectors | Cancer, Regenerative medicine, Auto-immunity indications, Digital solutions, Infectious disease |
| Geography | Global presence in the EU, US, and China |
| Offices | Ingelheim am Rhein, Germany, Cambridge, MA, United States, Hong Kong (Wanchai), China, Boston, United States, Shanghai, China |
Sources: S2 BIVF about us.
Data behind this graphic
| Item | Companies | Share |
|---|---|---|
| Exits and IPOs | 18 | 34.6% |
| Regenerative Medicine | 9 | 17.3% |
| Oncology | 6 | 11.5% |
| Anti-Infectives | 5 | 9.6% |
| Digital Health | 4 | 7.7% |
| Not actively managed Portfolio | 4 | 7.7% |
| Auto-Immunity | 3 | 5.8% |
| Other Technologies and Indications | 3 | 5.8% |
A company can carry more than one tag
Sources: S4 BIVF portfolio.
Data behind this graphic
| Measure | Value | Unit | Kind | Source |
|---|---|---|---|---|
| Headline size | EUR 350M | Fund size | Stated by the firm or its parent | S2 |
| Companies backed | 70+ | companies | Stated by the firm | S2 |
| Exits | 14 | exits | Stated by the firm | S4 |
| Companies on the firm's portfolio page | 52 | companies | Counted from the firm's own list | S4 |
Where it invests and who leads it
Geography
- Headquarters
- Ingelheim am Rhein, Germany
- Offices
- Ingelheim am Rhein, Germany
- Cambridge, MA, United States
- Hong Kong (Wanchai), China
- Boston, United States
- Shanghai, China
Investment regionsS2
- Global presence in the EU, US, and China
Key facts
| Fact | Value | Status | Source |
|---|---|---|---|
| Parent company | Boehringer Ingelheim (Privately held (no listing)) | Single source | S1 |
| Parent industry | Pharmaceuticals | Single source | S1 |
| Founded | 2010 | Single source | S2 |
| Headquarters | Ingelheim am Rhein, Germany | Single source | S5 |
| Status | Active | Single source | S1 |
| Capital source | Parent company only | Single source | S2 |
| Headline size | EUR 350M (Fund size) | Single source | S2 |
| Companies backed | 70+ | Single source | S2 |
| Exits | 14 total | Single source | S4 |
| People on the team page | 25 | Single source | S3 |
| Stages | Seed, Series A | Single source | S2 |
Portfolio
The firm's portfolio page lists 52 companies: 30 active, 18 exited.S4
The firm also states 70+ companies backed. The page list and the stated total measure different things.S2
| Tag | Companies | Share |
|---|---|---|
| Active | 30 | 57.7% |
| Exited | 18 | 34.6% |
| Tag | Companies | Share |
|---|---|---|
| Anti-Infectives | 5 | 9.6% |
| Auto-Immunity | 3 | 5.8% |
| Digital Health | 4 | 7.7% |
| Oncology | 6 | 11.5% |
| Other Technologies and Indications | 3 | 5.8% |
| Regenerative Medicine | 9 | 17.3% |
| Not actively managed Portfolio | 4 | 7.7% |
| Exits and IPOs | 18 | 34.6% |
Every company on the Boehringer Ingelheim Venture Fund list
52 companies, as listed on the firm's own website: 30 active, 18 exited, 4 listed.S4 Read the firm's list.
Active 30
- Abalos Therapeutics
- Acousia Therapeutics
- Aignostics
- ArrePath
- Asgard Therapeutics
- Aurobac Therapeutics
- Bodyport
- Brainomix
- C-mo Medical Solutions
- Centauri Therapeutics
- DiogenX
- EvlaBio
- HepaRegenix
- Libra Therapeutics
- Nuevocor
- Obulytix
- ProTgen
- QUANTRO Therapeutics
- Refoxy Pharmaceuticals
- Rewind Therapeutics
- Rgenta
- RiboX Therapeutics
- RinRi Therapeutics
- smartbax
- STRM.BIO
- SwitchKine
- Synthetica Pioneering
- Tacalyx
- TECregen
- Topas Therapeutics
Exited 18
- Abexxa Biologics
- AgomAb Therapeutics
- Amal Therapeutics
- ArmaGen Technologies
- Dopavision
- Home
- Hookipa Pharma
- ICD Therapeutics
- Imcheck Therapeutics
- NBE Therapeutics
- Okairos
- Our portfolio
- Rigontec
- STAT Dx
- T3 Pharmaceuticals
- Tilos Therapeutics
- ViraTherapeutics
- xCures
Listed 4
- eTheRNA immunotherapies
- Optina Diagnostics
- T-knife
- Wellth
For founders
| Item | What the firm says | Source |
|---|---|---|
| Stages | Seed, Series A | S2 |
| Leads rounds | Yes. "The financing was led by the Boehringer Ingelheim Venture Fund (BIVF)" | S6 |
| Beyond capital | Company formation expertise; board seat on portfolio companies; Team members each have more than 10 years in pharmaceutical R&D before investing | S2 |
| Contact form | www.boehringer-ingelheim-venture.com/contact | S5 |
Recent rounds
Fund vehicles
| Vehicle | Size | Year | Note | Source |
|---|---|---|---|---|
| BIVF evergreen fund | EUR 350M | 2010 | Established 2010; 'EUR 350M evergreen fund' | S2 |
Notable outcomes
IPOs and acquisitions of portfolio companies. Price shown only where published.
| Company | Type | Year | Acquirer or exchange | Price | Source |
|---|---|---|---|---|---|
| Hookipa Pharma | IPO | Listed (portfolio page 'Exits and IPOs'; exchange not stated) | S4 |
History
Where sources disagree
- Companies backed: invested in 70 companies and selected fund-in-fund opportunities (home page) (S1) vs > 70 investments (about page) (S2) vs over 70 companies incl. 7 fund-in-fund investments (portfolio page) (S4) vs over 40 active portfolio companies (about/portfolio page) (S2). Cumulative 70+ vs active 40+.S1S2S4S2
- Exits: 14 exited (about and portfolio page text) (S2) vs 18 names under Exits and IPOs filter (portfolio page) (S4). Text count vs filter list differ; both kept.S2S4
Official pages
Read the firm's own pages for current information.
Sources
- S1BIVF homeFirm
- S2BIVF about usFirm
- S3BIVF teamFirm
- S4BIVF portfolioFirm
- S5BIVF contactFirm
- S6TECregen CHF 10 million seed financing led by BIVF (HTGF news)Portfolio company
- S7STRM.BIO $8 million Series Seed 2 (PR Newswire)Portfolio company
- S8Cloverleaf Bio $33M seed led by 4BIO Capital (GlobeNewswire)Portfolio company
Disclaimer and corrections
Not affiliated. This page is not affiliated with, endorsed by or sponsored by Boehringer Ingelheim Venture Fund or any company named on it. Names and trademarks belong to their owners. Informational only. This is a public-source reference. It is not investment, legal or tax advice and not an offer or solicitation. Sources. Each figure names its source. Figures may have changed. Please read the firm's official pages, linked above. Corrections and takedown. To report an error or ask for a change or removal, use the correction form or email Richard@CorporateVentureCapital.com.
Spotted a mistake? Report a correction.